Genomic instability and chromosomal abnormalities are common features of cancer. Understanding these structural aberrations can provide insight into cancer etiology. Chromosomal abnormalities in cancer include gene fusions, chromosome rearrangements, and copy number variants (CNVs).
Sequencing- and microarray-based technologies offer complementary approaches for identifying chromosomal abnormalities in cancer.
Gene fusions resulting from chromosome translocations are a common chromosomal abnormality in cancer, often driving tumorigenesis. Paired-end RNA sequencing (RNA-Seq) enables researchers to identify non-contiguous sequences accurately by sequencing both ends of an insert.
Learn More About RNA-SeqMate pair sequencing is designed to detect structural variants. It provides sequence-specific information about each end of large DNA fragments for a comprehensive assessment of structural variants and chromosomal breakpoints and rapid identification of chromosomal abnormalities in cancer.
Learn More About Mate Pair SequencingMicroarrays are ideal for detecting CNVs, copy-neutral loss of heterozygosity, low-level mosaicism, and heterogeneity in cancer samples. Thousands of cytogenetically relevant genes are assessed in parallel to provide comprehensive coverage of chromosomal abnormalities in cancer.
Learn More About ArraysLab analyzes chromosomal abnormalities and disease connection.
Dr. Trilochan Sahoo discusses microarray-based cytogenetic testing to detect chromosomal abnormalities in cancer.
An overview of recent cancer research publications featuring Illumina technology.
An overview of recent research publications exploring the interaction between tumor cells and the immune system.
Laboratory adopts the newest technologies to analyze chromosomal abnormalities and their connection to disease.